Finding a model, finding a cure

May 14, 2001

A major hurdle in the development of an animal model of hereditary breast cancer in humans has been overcome.

Breast cancer is the most prevalent type of cancer in women, with 192,000 new cases expected this year in the US alone. Despite extensive research efforts, scientists have been unable develop a mouse model of hereditary breast cancer. Until now.

As published in the May 15th issue of Genes & Development, a collaboration of researchers from Columbia University and the Dana-Farber Cancer Institute have generated a mouse strain with an inherited mutation in Brca1. The breast and ovarian cancer susceptibility gene, Brca1, is the most commonly detected genetic mutation in familial breast and ovarian cancer. Although structural analysis and in vitro cell culture studies have yielded some clues, the precise function of BRCA1 remains unknown. This work by Dr. Efstratiadis and colleagues represents an enormous advance in the determination of BRCA1 function in tumorigenesis.

Several previous attempts have been made to generate BRCA1-deficient mice. However, these attempts were unsuccessful due to the embryonic death of the mice that had two deficient copies of Brca1, and the fact that mice with only one defective copy of Brca1 did not develop tumors. Dr. Efstratiadis and colleagues modeled their experimental approach after a human breast cancer patient who had inherited homozygous mutations in Brca1 that presumably led to the production of a shortened, or truncated, BRCA1 protein. The scientists generated a mouse strain with a truncating Brca1 mutation that similarly eliminates the C-terminal portion of the BRCA1 protein.

These BRCA1 hypomorphic mice are viable, and they develop a variety of tumors, including breast tumors. As 1 in 9 women will be diagnosed with breast cancer in her lifetime, this work has widespread implications as a therapeutic and research model for hereditary breast cancer.
-end-


Cold Spring Harbor Laboratory

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.